The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.
Monod
M
M
Service de Dermatologie/DHURDV, Centre Hospitalier Universitaire Vaudois, Lausanne, Suisse. Monod@chuv.hospvd.ch
Borg-von Zepelin
M
M
Telenti
A
A
Sanglard
D
D
D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D002176:Candida albicans / Q000201:enzymology*; D002177:Candidiasis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006801:Humans; D019469:Indinavir / Q000494:pharmacology; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D010843:Pichia / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D019438:Ritonavir / Q000494:pharmacology; D019258:Saquinavir / Q000494:pharmacology
D017320:HIV Protease Inhibitors; D007527:Isoenzymes; D011993:Recombinant Fusion Proteins; D019469:Indinavir; D016282:Aspartic Acid Endopeptidases; D019258:Saquinavir; D019438:Ritonavir